DOCSLIB.ORG

G/MA/QR/N/KAZ/3/Rev.2 8 De Junio De 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

G/MA/QR/N/KAZ/3/Rev.2 8 de junio de 2021 (21-4693) Página: 1/94 Comité de Acceso a los Mercados Original: inglés NOTIFICACIÓN DE CONFORMIDAD CON LA DECISIÓN SOBRE EL PROCEDIMIENTO DE NOTIFICACIÓN DE RESTRICCIONES CUANTITATIVAS KAZAJSTÁN Revisión La siguiente comunicación, de fecha 4 de mayo de 2021, se distribuye a petición de la delegación de Kazajstán. A. Miembro notificante: República de Kazajstán B. Fecha de la notificación: 7 de mayo de 2021 C. Primera notificación: Sí No, la última notificación se presentó con la signatura (signatura del documento): G/MA/QR/N/KAZ/3/Rev.1 D. Tipo de notificación: 1. Completa (es decir, notificación de todas las restricciones cuantitativas en vigor) 2. Cambios de una notificación presentada anteriormente con la signatura (signatura del documento) consistentes en lo siguiente: 2.1 Establecimiento de nuevas restricciones, enumeradas en la sección 1. 2.2 Eliminación de restricciones, como se describe en la casilla G infra. 2.3 Modificación de una restricción notificada anteriormente, como se indica en la sección 1. 3. Notificación inversa de restricciones mantenidas por (Miembro): E. La notificación proporciona información sobre el siguiente período bienal: 2020-2022 y se refiere a restricciones en vigor al 10 de septiembre de 2020 F. La presente notificación contiene información* relativa a: Sección 1: Lista de restricciones cuantitativas actualmente en vigor. Sección 2: Referencia a otras notificaciones presentadas a la OMC que contengan información sobre restricciones cuantitativas actualmente en vigor e información adicional. G. Observaciones de carácter general, con inclusión de una descripción de la eliminación de restricciones notificada en el apartado 2.2 de la casilla D y la fecha en que esas restricciones dejaron de estar en vigor. La presente notificación revisada tiene por objeto corregir un problema de numeración y añadir información que faltaba en las columnas 5 y 6 del anexo 1 del documento G/MA/QR/N/KAZ/3/Rev.1. * En inglés solamente. Section 1: List of quantitative restrictions that are currently in force QR General Type of Tariff line Detailed Product Description WTO National legal basis Administration, No. description of restriction code (s) affected, Justification and entry into force modification of the restriction based on HS and Ground previously (2017) for notified Restriction, measures, and e.g. Other other International comments Commitments 1 2 3 4 5 6 7 1 Prohibition to CP of 2903 77 600 0 Fluorotrichloromethane CFCl3 Article XX(b) Annex No. 1 to Decision import/export of CP-X GATT No. 30 of the Board of the ozone destroying Eurasian Economic substances Montreal Commission dd. Protocol on 21.04.2015 (as revised in Substances that Decision No. 99 of the G/MA/QR/N/KAZ/3/Re Deplete the Board of the Eurasian Ozone Layer Economic Commission signed on 16 dd. 30.08.2016); (as September revised in Decision No. - 1987 145 of the Board of the 2 Eurasian Economic - Commission dd. 15.11.2016). Article 46 of the EAEU Treaty of 29 May 2014 v.2 and paragraphs 4 and 37 of the Protocol on Non- Tariff Measures Concerning Third Countries (Annex No. 7 to the EAEU Treaty of 29 May 2014) of 2903 77 600 0 Dichlorodifluoromethane CF2Cl2 of 2903 77 600 0 1,1,2-trichlorotrifluoroethane C2F3Cl3 of 2903 77 600 0 1,1,2,2-tetrafluorodichloroethane C2F4Cl2 of 2903 77 600 0 Pentafluorochloroethane C2F5Cl 2903 76 100 0 Bromochlorodifluoromethane CF2BrCl 2903 76 200 0 bromotrifluoromethane CF3Br of 2903 76 900 0 1,1,2,2-dibromotetrafluoroethane C2F4Br2 QR General Type of Tariff line Detailed Product Description WTO National legal basis Administration, No. description of restriction code (s) affected, Justification and entry into force modification of the restriction based on HS and Ground previously (2017) for notified Restriction, measures, and e.g. Other other International comments Commitments 1 2 3 4 5 6 7 of 2903 77 900 0 Chlorotrifluoromethane CF3Cl of 2903 77 900 0 Pentachlorofluoroethane C2FCl5 of 2903 77 900 0 tetrachlorodifluoroethane C2F2Cl4 of 2903 77 900 0 Heptachlorofluoropropane C3FCl7 of 2903 77 900 0 hexachlorodifluoropropane C3F2Cl6 of 2903 77 900 0 Pentachlorotrifluoropropane C3F3Cl5 G/MA/QR/N/KAZ/3/Re of 2903 77 900 0 Tetrachlorotetrafluoropropane C3F4Cl4 of 2903 77 900 0 trichloropentafluoropropane C3F5Cl3 - of 2903 77 900 0 dichlorohexafluoropropane 3 C3F6Cl2 - of 2903 77 900 0 chloroheptafluoropropane C3F7Cl 2903 14 000 0 carbon tetrachloride, or tetrachloromethane CCl4 of 2903 19 000 0 methyl chloroform, i.e. 1,1,1- trichloroethane v.2 1 C2H3Cl3 of 2903 79 300 0 dibromofluoromethane CHFBr2 of 2903 79 300 0 bromodifluoromethane CHF2Br of 2903 79 300 0 bromofluoromethane CH2FBr of 2903 79 300 0 tetrabromofluoroethane C2HFBr4 of 2903 79 300 0 tribromodifluoroethane C2HF2Br3 of 2903 79 300 0 dibromotrifluoroethane C2HF3Br2 of 2903 79 300 0 bromotetrafluoroethane C2HF4Br of 2903 79 300 0 tribromofluoroethane C2H2FBr3 of 2903 79 300 0 dibromodifluoroethane C2H2F2Br2 of 2903 79 300 0 bromotrifluoroethane C2H2F3Br of 2903 79 300 0 dibromofluoroethane C2H3FBr2 of 2903 79 300 0 bromodifluoroethane C2H3F2Br 1 This formula does not apply to 1,1,2-trichloroethane. QR General Type of Tariff line Detailed Product Description WTO National legal basis Administration, No. description of restriction code (s) affected, Justification and entry into force modification of the restriction based on HS and Ground previously (2017) for notified Restriction, measures, and e.g. Other other International comments Commitments 1 2 3 4 5 6 7 of 2903 79 300 0 bromofluoroethane C2H4FBr of 2903 79 300 0 hexabromofluoropropane C3HFBr6 of 2903 79 300 0 pentabromodifluoropropane C3HF2Br5 of 2903 79 300 0 tetrabromotrifluoropropane C3HF3Br4 of 2903 79 300 0 tribromotetrafluoropropane C3HF4Br3 G/MA/QR/N/KAZ/3/Re of 2903 79 300 0 dibromopentafluoropropane C3HF5Br2 of 2903 79 300 0 bromohexafluoropropane C3HF6Br of 2903 79 300 0 pentabromofluoropropane C3H2FBr5 - 4 of 2903 79 300 0 tetrabromodifluoropropane - C3H2F2Br4 of 2903 79 300 0 tribromotrifluoropropane C3H2F3Br3 of 2903 79 300 0 dibromotetrafluoropropane C3H2F4Br2 v.2 of 2903 79 300 0 bromopentafluoropropane C3H2F5Br of 2903 79 300 0 tetrabromofluoropropane C3H3FBr4 of 2903 79 300 0 tribromodifluoropropane C3H3F2Br3 of 2903 79 300 0 dibromotrifluoropropane C3H3F3Br2 of 2903 79 300 0 bromotetrafluoropropane C3H3F4Br of 2903 79 300 0 tribromofluoropropane C3H4FBr3 of 2903 79 300 0 dibromodifluoropropane C3H4F2Br2 of 2903 79 300 0 bromotrifluoropropane C3H4F3Br of 2903 79 300 0 dibromofluoropropane C3H5FBr2 of 2903 79 300 0 bromodifluoropropane C3H5F2Br of 2903 79 300 0 bromofluoropropane C3H6FBr 2903 39 110 0 bromomethane CH3Br QR General Type of Tariff line Detailed Product Description WTO National legal basis Administration, No. description of restriction code (s) affected, Justification and entry into force modification of the restriction based on HS and Ground previously (2017) for notified Restriction, measures, and e.g. Other other International comments Commitments 1 2 3 4 5 6 7 of 3824 71 000 0 Cooling mixtures of 3824 72 000 0 of 3824 74 000 0 of 3824 75 000 0 of 3824 76 000 0 of 3824 77 000 0 of 3824 78 of 3824 79 000 0 G/MA/QR/N/KAZ/3/Re 8415 10 Air conditioners and heat pumps 8415 81 00 8415 82 000 0 8418 61 00 of 8418 69 000 - 5 of 8418 10 200 Refrigerators - of 8418 10 800 of 8418 50 of 8418 69 000 of 8418 Ice-making machines, milk of 8419 cooling units v.2 of 8418 10 200 Freezing compartments of 8418 10 800 8418 30 200 8418 30 800 8418 40 200 8418 40 800 of 8418 50 of 8418 69 000 of 8418 69 000 Air driers of 8479 89 9701 of 8479 89 970 8 of 3921 11 000 0 Insulating boards, plates, panels and cellular of 3921 12 000 0 pipe coatings, using cellulating of 3921 13 100 0 agents as foaming agents of 3921 13 900 0 containing ozone-depleting of 3921 14 000 0 substances of 3921 19 000 0 QR General Type of Tariff line Detailed Product Description WTO National legal basis Administration, No. description of restriction code (s) affected, Justification and entry into force modification of the restriction based on HS and Ground previously (2017) for notified Restriction, measures, and e.g. Other other International comments Commitments 1 2 3 4 5 6 7 of 3907 20 200 1 Components, formulations based of 3907 20 200 9 on polyesters (polyols) for the production of expanded polyurethane (component A) of 8424 10 000 0 Portable fire extinguishers2 2 Prohibition to P of 2805 40 Wastes that contain any of the Article XX(b) Annex No. 1 to Decision import of of 7204 following substances as a GATT No. 30 of the Board of hazardous of 7404 00 component or contaminant: the Eurasian Economic G/MA/QR/N/KAZ/3/Re wastes Movements of Commission dd. Hazardous 21.04.2015) Wastes and (as revised in Decision their Disposal No. 145 of the Board of signed in Basel the Eurasian Economic - 6 of 22 March Commission dd. - 1990 15.11.2016 of 7503 00 arsenic, arsenic compounds of 7602 00 mercury, mercury compounds of 7802 00 000 0 (excluding mercury lamps and luminescent tubes) v.2 of 7902 00 000 0 Zinc waste and scrap of 8002 00 000 0 Tin and products made from it of 8101 97 000 0 other non-precious metal waste of 8102 97 000 0 and scrap of 8103 30 000 0 of 8104 20 000 0 of 8105 30 000 0 of 8106 00 100 0 of 8107 30 000 0 of 8108 30 000 0 of 8109 30 000 0 of 8110 20 000 0 of 8111 00 190 0 2 Except for products containing ozone-depleting substances controlled by the export control system of the Eurasian Economic Union Member State being the State of departure/destination of these commodities.
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs

    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
  • Toxicology Report Division of Toxicology Daniel D

    Toxicology Report Division of Toxicology Daniel D

    Franklin County Forensic Science Center Office of the Coroner Anahi M. Ortiz, M.D. 2090 Frank Road Columbus, Ohio 43223 Toxicology Report Division of Toxicology Daniel D. Baker, Chief Toxicologist Casey Goodson Case # LAB-20-5315 Date report completed: January 28, 2021 A systematic toxicological analysis has been performed and the following agents were detected. Postmortem Blood: Gray Top Thoracic ELISA Screen Acetaminophen Not Detected ELISA Screen Barbiturates Not Detected ELISA Screen Benzodiazepines Not Detected ELISA Screen Benzoylecgonine Not Detected ELISA Screen Buprenorphine Not Detected ELISA Screen Cannabinoids See Confirmation ELISA Screen Fentanyl Not Detected ELISA Screen Methamphetamine Not Detected ELISA Screen Naltrexone/Naloxone Not Detected ELISA Screen Opiates Not Detected ELISA Screen Oxycodone/Oxymorphone Not Detected ELISA Screen Salicylates Not Detected ELISA Screen Tricyclics Not Detected Page 1 of 4 Casey Goodson Case # LAB-20-5315 GC/FID Ethanol Not Detected GC/MS Acidic/Neutral Drugs None Detected GC/MS Nicotine Positive GC/MS Cotinine Positive Reference Lab Delta-9-THC 13 ng/mL Reference Lab 11-Hydroxy-Delta-9-THC 1.2 ng/mL Reference Lab 11-Nor-9-Carboxy-Delta-9-THC 15 ng/mL Postmortem Urine: Gray Top Urine GC/MS Cotinine Positive This report has been verified as accurate and complete by ______________________________________ Daniel D. Baker, M.S., F-ABFT Cannabinoid quantitations in blood were performed by NMS Labs, Horsham, PA. Page 2 of 4 Casey Goodson Case # LAB-20-5315 Postmortem Toxicology Scope of Analysis Franklin County Coroner’s Office Division of Toxicology Enzyme Linked Immunosorbant Assay (ELISA) Blood Screen: Qualitative Presumptive Compounds/Classes: Acetaminophen (cut-off 10 µg/mL), Benzodiazepines (cut-off 20 ng/mL), Benzoylecgonine (cut-off 50 ng/mL), Cannabinoids (cut-off 40 ng/mL), Fentanyl (cut-off 1 ng/mL), Methamphetamine/MDMA (cut-off 50 ng/mL), Opiates (cut-off 40 ng/mL), Oxycodone/Oxymorphone (cut-off 40 ng/mL), Salicylates (50 µg/mL).
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci

    Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci

    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
  • Conversion Factors Psychotropics

    Conversion Factors Psychotropics

    Green List 30th edition, 2019 Annex to the annual statistical report on International Narcotics Control Board psychotropic substances (form P) List of Psychotropic Substances under International Control In accordance with the Convention on Psychotropic Substances of 1971 UPDATES • Inclusion of 5 new substances in Schedule II : ADB-CHMINACA, ADB-FUBINACA, CUMYL- 4CN-BINACA, N-ETHYLNORPENTYLONE and FUB-AMB. The Green List has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical report on psychotropic substances (form P) and the quarterly statistics of imports and exports of substances in Schedule II of the Convention on Psychotropic Substances of 1971 (form A/P). For information on the names used for substances under international control and preparations containing such substances, as well as on chemical and structural formulae and other techni cal information, see Multilingual Dictionary of Narcotic Drugs and Psychotropic Substances under International Control .1 __________________ 1 United Nations publication, Sales No. M.06.XI.16. V.19-08673 (E) *1908673* The Green List is divided into three parts: Part one. Substances in Schedules I, II, III and IV of the Convention on Psychotropic Substances of 1971; Part two. Pure drug content of bases and salts of psychotropic substances under international control; Part three. Prohibition of and restrictions on export and import pursuant to article 13 of the Convention on Psychotropic Substances of 1971. 2 Part one. Substances in Schedules I, II, III and IV of the Convention on Psychotropic Substances of 1971 Psychotropic substances under international control are presented in the schedules below. Where an international non-proprietary name (INN) is available for a substance, that INN is given in the left -hand column.
  • Health and Human Services Committee

    Health and Human Services Committee

    HEALTH AND HUMAN SERVICES COMMITTEE MEETING AGENDA Date & Time of Meeting: Monday, August 26, 2019 at 4:00 p.m. Meeting Location: Courthouse Assembly Room (B105), 500 Forest Street, Wausau WI Health & Human Services Committee Members: Matt Bootz, Chair; Tim Buttke, Vice-chair, Bill Miller; Donna Krause, Mary Ann Crosby, Maynard Tremelling, Katie Rosenberg Marathon County Mission Statement: Marathon County Government serves people by leading, coordinating, and providing county, regional, and statewide initiatives. It directly or in cooperation with other public and private partners provides services and creates opportunities that make Marathon County and the surrounding area a preferred place to live, work, visit, and do business. (Last updated: 12-20-05) Health & Human Services Committee Mission Statement: Provide leadership for the implementation of the strategic plan, monitoring outcomes, reviewing and recommending to the County Board policies related to health and human services initiatives of Marathon County. 1. Call Meeting to Order 2. Public Comment (15 minute limit) 3. Approval of the July 22, 2019, Committee meeting minutes. 4. Policy Issues for Discussion and Possible Action: A. Referral from the Board of Health – Creation of a Workplace Naloxone Use Program 1) Policy Question – should the committee direct the County Administrator to develop a workplace Naloxone Use Program? 5. Operational Functions required by Statute, Ordinance, or Resolution: None 6. Educational Presentations/Outcome Monitoring Reports and Committee Discussion A. Marathon County 2018-2022 Strategic Plan – discussion with Board Vice-Chair 1) Review of Objectives where the committee has been designated at “lead committee” 2) What discussions has the committee had to move the objectives forward and what discussions should it have in the future? B.
  • Doping Control of Athletes

    Doping Control of Athletes

    trends in analytical chemistry, vol. 7, no. IO, I988 375 trends Doping control of athletes E. G. de Jong*, I?. A. A. Maes and The definition of the Council of Europe for doping J. M. van Rossum is2: Utrecht, Netherlands ‘The administration to or the use by a healthy indi- vidual in any way of compounds which are not natu- History ral to the organism or the use of physiological com- The origin of the word doping is not certain. It first pounds in abnormal doses or in an abnormal way appeared in the English dictionaries at the end of the with the only purpose to artificially and dishonestly nineteenth century. The first reference to the use of influence the performance of this person during doping by athletes was in 1864 during swimming competition.’ competitions that were held in the canals of Amster- Another possible definition is: dam. The use of what is known as a ‘speedball’, a ‘The use of compounds which are not synthesized mixture of heroine and cocaine, by cyclists was de- by the human body or the use of endogenous com- scribed in 1869. In 1904 the Russian chemist pounds in excessive doses with the aim to improve Bukowski was able to identify some alkaloids in the performance in sport competitions.’ saliva of horses’. A simpler definition is: Australia was the first country to take measures ‘The use of forbidden drugs. ’ against doping in sports in 1962, and England fol- The last definition can only be used when we have lowed with the drugs bill in 1964.
  • New Drugs in Europe, 2012 Europe, in Drugs New

    New Drugs in Europe, 2012 Europe, in Drugs New

    ISSN 1977-7841 New drugs in Europe, 2012 EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA 2012 New drugs in Europe, 2012 EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, the EU Member States or any institution or agency of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answersto your questions about the European Union. Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. Cataloguing data can be found at the end of this publication. Luxembourg: Publications Office of the European Union, 2013 ISBN 978-92-9168-650-6 doi:10.2810/99367 © European Monitoring Centre for Drugs and Drug Addiction, 2013 Cais do Sodré, 1249-289 Lisbon, Portugal Tel. +351 211210200 • [email protected] • www.emcdda.europa.eu © Europol, 2013 Eisenhowerlaan 73, 2517 KK, The Hague, the Netherlands Tel.
  • Introduced B.,Byhansen, 16

    Introduced B.,Byhansen, 16

    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
  • List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of narcotic substances circulation of which is restricted in Uzbekistan 1. 2C-B(4-bromo-2,5-dimethoxyphenethylamine) 2. 3-methylfentanyl 3. 3-methylthiofentanyl 4. 3-Monoacetylmorphine 5. 4-methylaminorex 6. 6- Monoacetylmorphine 7. Acetorphine 8. Acetyl Dihydrocodeine 9. Acetyl-alfametilfentanil 10. Acetylated opium 11. Acetylcodeine 12. Acetylmethadol 13. Alfametadol 14. Alfatsetilmetadol 15. all fungi that contain Psilocine and Psilocybine 16. Allylprodine 17. Alpha Methylfentanyl 18. Alpha Metiltiofentanil 19. Alphaprodine 20. Anileridin 21. Benzethidine 22. Benzylmorphine 23. Betacetylmethadol 24. Betahydroxyfentanyl 25. Betameprodine 26. Betamethadol 27. Betaprodine 28. Bezitramide 29. Cannabis oil (hashish oil) 30. Cannabis, marihuana 31. Cathine ((+)-norpseudoephedrine) 32. Cathinone (l-alpha-aminopropiofenon) 33. Clonitazene 34. Cocaine 35. Codoxime 36. d- Methadone 37. DB [L-(3,4 - methylenedioxyphenyl) -2 butanamine] 38. Desmethylprodine; MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 39. Desomorphine 40. DET (N,N-diethyltryptamine) 41. Dexamphetamine 42. Diampromide 43. Diethyl phosphate 44. Diethylthiambutene 45. Dihydromorphine 46. Dimenoxadol 47. Dimepheptanol 48. Dimethylthiambutene 49. Dioxaphetyl butyrate 50. Diphenoxine 51. Dipipanone 52. DMA (2,5-dimethoxyamphetamine) 53. DMGP (dimetilgeptilpiran) 54. DMT (dimethyltryptamine) 55. DOB (d, L-2,5-dimethoxy-4-bromo-amphetamine) 56. DOC (d, L-2,5-dimethoxy-4-chloro-amphetamine) 57. DOET (2,5-dimethoxy-4-ethylamphetamine) 58. Drotebanol 59. Ecgonine 60. Ephedrone 61. Ethylmethylthiambutene 62. Eticyclidine 63. Etonitazene 64. Etorphine 65. Etoxeridine 66. Etryptamine 67. Furethidine 68. Hashish (Anasha, cannabis resin) 69. Heroin (Diacetylmorphine) 70. Hydrocodone 71. Hydrocodone phosphate 72. Hydromorphinol 73. Hydromorphone 74. Isomethadone 75. Ketobemidone 76. Khat 77. L- Methadone 78. Levomethorphan 79. Levomoramide 80. Levophenacylmorphan 81. Levorphanol 82. Lysergic acid and its preparations, that include d-Lysergide (LSD, LSD-25) 83.
  • Decision of the Government of the Russian Federation No

    Decision of the Government of the Russian Federation No

    DECISION OF THE GOVERNMENT OF THE RUSSIAN FEDERATION NO. 681 OF JUNE 30, 1998 ON THE APPROVAL OF THE LIST OF NARCOTIC DRUGS, PSYCHOTROPIC SUBSTANCES AND THEIR PRECURSORS THAT SHALL BE SUBJECT TO CONTROL IN THE RUSSIAN FEDERATION In accordance with the Federal Law on Narcotic Drugs and Psychotropic Substances (Sobraniye zakonodatelstva Rossiyskoy Federatsii, 1998, No. 2, item 219) the Government of the Russian Federation resolves: To approve the annexed enumeration of narcotic drugs, psychotropic substances and their precursors that shall be subject to control in the Russian Federation. To establish that the amendment of the said enumeration shall be carried out on presentation of the Ministry of Public Health of the Russian Federation jointly with the Ministry of Internal Affairs of the Russian Federation. Chairman of the Government of the Russian Federation Sergey Kirienko Enumeration of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (Approved by the Decision of the Government of the Russian Federation No. 681 of June 30, 1998) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Prohibited in Accordance with the Legislation of the Russian Federation and the International Treaties of the Russian Federation (List I) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Restricted and in Whose Respect Control Measures Shall Be Established in Accordance with the Legislation of
  • WO 2017/066488 Al

    WO 2017/066488 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/066488 A l 2 0 April 2017 (20.04.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/5415 (2006.01) A61P 1/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/0569 10 HN, HR, HU, ID, IL, EST, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 October 2016 (13.10.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/240,965 13 October 2015 (13. 10.2015) US (84) Designated States (unless otherwise indicated, for every 62/300,014 25 February 2016 (25.02.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: CHARLESTON LABORATORIES, INC.